Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.

To study the evolution of camptothecin (CPT) resistance, we have established two small-cell lung cancer cell lines with low (3.2-fold, NYH/CAM15) and high (18-fold, NYH/CAM50) resistance to CPT by stepwise drug exposure. NYH/CAM50 cells had reduced topoisomerase I (topo I) content and activity, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorensen, M., Sehested, M., Christensen, I. J., Larsen, J. K., Jensen, P. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150415/
https://www.ncbi.nlm.nih.gov/pubmed/9649127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150415/
https://www.ncbi.nlm.nih.gov/pubmed/9649127

Ejemplares similares